Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

Summary

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 7, 3, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Colon Cancer, Dedifferentiated Liposarcoma, Epithelial Ovarian Cancer, Esophageal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Liposarcoma, Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Thymic Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Lung Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Nonmelanomatous Skin Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Type 2 Diabetes and Well Differentiated Liposarcoma.

The latest report Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharm Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Rizen (Suzhou) Biosciences Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Pharmaceutical Group Co Ltd
SignalRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Sino Biopharmaceutical Ltd
Tetranov International Inc
Tiziana Life Sciences Plc
ViroStatics SRL
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BEBT-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-16350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-3002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCN-437c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-10342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lerociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-108110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06873600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TQ-05510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Dec 11, 2019: G1 Therapeutics presents updated data from phase 1b/2a trial of oral CDK4/6 inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
Dec 11, 2019: Combining endocrine therapy with a CDK4/6 Inhibitor results in similar response rates to chemotherapy for high-risk Luminal B Breast Cancer
Dec 08, 2019: New test predicts chance of living more than a year on targeted breast cancer treatment
Nov 28, 2019: NICE recommends Pfizer’s Ibrance for NHS use through the CDF
Nov 11, 2019: Novartis’ Kisqali (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium (SMC) for the treatment of patients with the most common form of advanced breast cancer
Oct 03, 2019: MEI pharma announces updated clinical data from voruciclib
Sep 30, 2019: ESMO 2019: Kisqali shows superior overall survival in breast cancer
Sep 29, 2019: Verzenio (abemaciclib) significantly extends life by a Median of 9.4 months for women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 study
Sep 28, 2019: G1 Therapeutics presents updated data at ESMO 2019 from randomized phase 2 trial of Trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer demonstrating significant improvement in overall survival
Sep 26, 2019: Addition of KISQALI to drug plan in Quebec expands access to treatment for metastatic breast cancer
Sep 24, 2019: Pfizer presents new evidence of IBRANCE (palbociclib) effectiveness in HR+, HER2- metastatic breast cancer patients in four real-world studies at ESMO Congress 2019
Sep 23, 2019: Lilly Oncology to present robust data on VERZENIO (abemaciclib) at ESMO 2019
Sep 10, 2019: G1 Therapeutics to present new clinical data on Lerociclib (G1T38) at European Society for Medical Oncology (ESMO) 2019 Congress
Sep 10, 2019: G1 Therapeutics to present new clinical data on Trilaciclib at European Society for Medical Oncology (ESMO) 2019 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Beta Pharma Inc, H2 2019
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by ESSA Pharma Inc, H2 2019
Pipeline by Fochon Pharmaceutical Ltd, H2 2019
Pipeline by G1 Therapeutics Inc, H2 2019
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H2 2019
Pipeline by HEC Pharm Co Ltd, H2 2019
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by MEI Pharma Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Onconova Therapeutics Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019
Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019
Pipeline by Shanghai Pharmaceutical Group Co Ltd, H2 2019
Pipeline by SignalRx Pharmaceuticals Inc, H2 2019
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2019
Pipeline by Sino Biopharmaceutical Ltd, H2 2019
Pipeline by Tetranov International Inc, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by ViroStatics SRL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook